Status:
RECRUITING
The α-gal Syndrome - Investigating Immune Reactions to Tick Bites Leading to Inflammation and Allergic Sensitization
Lead Sponsor:
Luxembourg Institute of Health
Collaborating Sponsors:
Luxembourg National Research Fund (FNR)
Centre Hospitalier du Luxembourg
Conditions:
Alpha-Gal Syndrome
Immune and Antibody Responses After Tick Bite
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this clinical trial is to follow immune response and antibody build-up in individuals bitten by a tick. Participants are invited to enroll within 48 hours after the tick removal and donate...
Detailed Description
Ticks bearing pathogens can transmit infectious diseases such as Lyme borreliosis, tick-borne encephalitis and others. Recently, a non-infectious human disease, namely the alpha-gal syndrome (AGS), wa...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Individuals aged ≥ 18 years, Male and Female.
- Experience of a tick bite: the tick has been removed less than 48 hours ago, or the tick is still attached to the skin and can be removed on site by the study nurse.
- Tick available for analysis.
- Informed consent signed.
- Exclusion criteria:
- Individuals \< 18 years of age, Male or Female.
- Individuals with an acute viral/bacterial inflammation.
- Individuals with an immune deficiency or under immunosuppressive treatments.
- Individuals in receipt with immunotherapy with omalizumab.
- Individuals with neurological diseases / impaired cognitive disorder.
Exclusion
Key Trial Info
Start Date :
July 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07177729
Start Date
July 1 2025
End Date
February 1 2027
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LCTR
Luxembourg, Luxembourg